Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity
Cisplatin (CDDP) is a well-known chemotherapeutic drug approved for various cancers. However, CDDP accumulates in the inner ear cochlea via organic cation transporter 2 (OCT2) and causes ototoxicity, which is a major clinical limitation. Since lansoprazole (LPZ), a proton pump inhibitor, is known to...
Saved in:
Main Authors: | Eri Wakai (Author), Kenji Ikemura (Author), Toshiro Mizuno (Author), Kazuhiko Takeuchi (Author), Satoshi Tamaru (Author), Masahiro Okuda (Author), Yuhei Nishimura (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity
by: Eri Wakai, et al.
Published: (2020) -
Lansoprazole Ameliorates Isoniazid-Induced Liver Injury
by: Eri Wakai, et al.
Published: (2024) -
Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy
by: Kenji Ikemura, et al.
Published: (2017) -
Apoptosis, autophagy, ferroptosis, and pyroptosis in cisplatin-induced ototoxicity and protective agents
by: Dingyuan Dai, et al.
Published: (2024) -
Ototoxicity in children receiving cisplatin chemotherapy
by: Hee Jin Jang, et al.
Published: (2010)